Aliases & Classifications for Vascular Dementia

MalaCards integrated aliases for Vascular Dementia:

Name: Vascular Dementia 12 15
Multi-Infarct Dementia 76 54 73
Dementia, Vascular 76 44 73
Dementia, Vascular, Susceptibility to 13
Vascular Dementia, Susceptibility to 6
Dementia, Multi-Infarct 44
Multi Infarct Dementia 12
Multifocal Dementia 12
Dementia Vascular 55


External Ids:

Disease Ontology 12 DOID:8725
ICD10 33 F01 F01.5 F01.1
ICD9CM 35 290.4
SNOMED-CT 68 56267009

Summaries for Vascular Dementia

NINDS : 54 Multi-infarct dementia (MID) is a common cause of memory loss in the elderly.  MID is caused by multiple strokes (disruption of blood flow to the brain).  Disruption of blood flow leads to damaged brain tissue.  Some of these strokes may occur without noticeable clinical symptoms. Doctors refer to these as “silent strokes.”  An individual having a silent stroke may not even know it is happening, but over time, as more areas of the brain are damaged and more small blood vessels are blocked, the symptoms of MID begin to appear.  MID can be diagnosed by an MRI or CT of the brain, along with a neurological examination. Symptoms include confusion or problems with short-term memory; wandering, or getting lost in familiar places; walking with rapid, shuffling steps; losing bladder or bowel control; laughing or crying inappropriately; having difficulty following instructions; and having problems counting money and making monetary transactions.  MID, which typically begins between the ages of 60 and 75, affects men more often than women. Because the symptoms of MID are so similar to Alzheimer’s disease, it can be difficult for a doctor to make a firm diagnosis.  Since the diseases often occur together, making a single diagnosis of one or the other is even more problematic. 

MalaCards based summary : Vascular Dementia, also known as multi-infarct dementia, is related to binswanger's disease and dementia. An important gene associated with Vascular Dementia is TNF (Tumor Necrosis Factor), and among its related pathways/superpathways are Selenium Micronutrient Network and Neuroscience. The drugs Citalopram and Memantine have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and cortex, and related phenotypes are homeostasis/metabolism and behavior/neurological

Disease Ontology : 12 A dementia that involves impairments in cognitive function caused by problems in blood vessels that feed the brain.

Wikipedia : 76 Vascular dementia, also known as multi-infarct dementia (MID) and vascular cognitive impairment (VCI),... more...

Related Diseases for Vascular Dementia

Diseases related to Vascular Dementia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 151)
# Related Disease Score Top Affiliating Genes
1 binswanger's disease 32.0 ACHE APOE APP MAPT NOTCH3
3 alzheimer disease 31.3 ACHE APOE APP BCHE CHAT CST3
4 vascular disease 30.7 ACE APOE CST3 MTHFR PON1 TNF
5 atherosclerosis susceptibility 30.1 APOE PON1 TNF
6 ischemia 30.1 ACE APP PON1 VEGFA
7 carotid stenosis 29.9 ACE APOE MTHFR TNF
8 frontotemporal dementia 29.8 ACHE APOE APP MAPT PSEN1
9 sleep apnea 29.8 ACE APOE TNF
10 hydrocephalus 29.7 APOE APP MAPT MBP
11 head injury 29.7 APOE CHAT
12 cerebrovascular disease 29.6 ACE ACHE APOE APP MAPT MTHFR
13 cerebral amyloid angiopathy, cst3-related 29.5 APOE APP CST3 MAPT PSEN1 SERPINA3
14 dementia, lewy body 29.5 ACHE APOE APP BCHE MAPT PSEN1
15 arteries, anomalies of 29.4 ACE APOE PON1 TNF VEGFA
16 heart disease 29.2 ACE APOE CST3 MTHFR PON1 TNF
17 alzheimer disease 2 29.1 APOE APP BCHE MAPT PSEN1 SERPINA3
18 myocardial infarction 29.0 ACE APOE CST3 MTHFR PON1 TNF
19 subcortical arteriosclerotic encephalopathy 11.1
20 cerebral arteriosclerosis 11.1
21 dementia - subcortical 11.0
22 cerebral arteriopathy, autosomal dominant, with subcortical infarcts and leukoencephalopathy, type 1 10.8
23 dementia pugilistica 10.5
24 cerebral arteriopathy, autosomal recessive, with subcortical infarcts and leukoencephalopathy 10.3
25 cerebral arteriopathy, autosomal dominant, with subcortical infarcts and leukoencephalopathy, type 2 10.3
26 simultanagnosia 10.3 APOE MAPT
27 moderate and severe traumatic brain injury 10.3 ACE APOE
28 posterior cortical atrophy 10.3 APOE MAPT
29 aging 10.3
30 uveoparotid fever 10.2 ACE TNF
31 subacute cutaneous lupus erythematosus 10.2 ACE TNF
32 alzheimer's disease 1 10.2 APOE APP
33 generalized atherosclerosis 10.2 ACE APOE
34 skin sarcoidosis 10.2 ACE TNF
35 nominal aphasia 10.2 MAPT PSEN1
36 progressive non-fluent aphasia 10.2 MAPT PSEN1
37 butyrylcholinesterase deficiency 10.2 ACHE BCHE
38 behavioral variant of frontotemporal dementia 10.2 MAPT PSEN1
39 depression 10.2
40 granulomatous dermatitis 10.2 ACE TNF
41 cerebral palsy 10.2 APOE MTHFR TNF
42 cerebral atherosclerosis 10.2 ACE APOE MTHFR
43 alzheimer disease 4 10.2 APOE PSEN1
44 hemifacial spasm 10.2 MTHFR VEGFA
45 semantic dementia 10.2 APOE MAPT PSEN1
46 aortic atherosclerosis 10.2 ACE APOE PON1
47 diabetes mellitus 10.1
48 coronary stenosis 10.1 ACE APOE PON1
49 early-onset, autosomal dominant alzheimer disease 10.1 APP PSEN1
50 critical limb ischemia 10.1 TNF VEGFA

Comorbidity relations with Vascular Dementia via Phenotypic Disease Network (PDN):

Acute Cystitis Cerebral Atherosclerosis
Schizophreniform Disorder

Graphical network of the top 20 diseases related to Vascular Dementia:

Diseases related to Vascular Dementia

Symptoms & Phenotypes for Vascular Dementia

MGI Mouse Phenotypes related to Vascular Dementia:

46 (show all 15)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.37 ACE ACHE APOE APP BCHE CHAT
2 behavior/neurological MP:0005386 10.33 ACE ACHE APOE APP CHAT MAPT
3 growth/size/body region MP:0005378 10.3 ACE ACHE APOE APP CHAT MAPT
4 cardiovascular system MP:0005385 10.28 ACE APOE APP CHAT CST3 MAPT
5 mortality/aging MP:0010768 10.28 ACE ACHE APOE APP BCHE CHAT
6 hematopoietic system MP:0005397 10.21 ACE ACHE APOE APP MAPT MBP
7 integument MP:0010771 10.13 APOE APP MAPT MTHFR NOTCH3 PSEN1
8 nervous system MP:0003631 10.13 ACHE APOE APP CHAT CST3 MAPT
9 muscle MP:0005369 10.1 ACHE APOE APP CHAT CST3 MAPT
10 reproductive system MP:0005389 9.97 ACE ACHE APOE APP BCHE CHAT
11 limbs/digits/tail MP:0005371 9.93 APOE CHAT MTHFR PSEN1 TNF VEGFA
12 neoplasm MP:0002006 9.85 ACE CST3 MAPT NOTCH3 TNF VEGFA
13 no phenotypic analysis MP:0003012 9.8 ACHE APOE APP MAPT MTHFR TNF
14 respiratory system MP:0005388 9.5 ACHE APOE CHAT NOTCH3 PSEN1 TNF
15 vision/eye MP:0005391 9.32 ACHE APOE CHAT MAPT MBP MTHFR

Drugs & Therapeutics for Vascular Dementia

Drugs for Vascular Dementia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 171)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Citalopram Approved Phase 4 59729-33-8 2771
Memantine Approved, Investigational Phase 4,Not Applicable 19982-08-2 4054
Dopamine Approved Phase 4,Phase 2,Phase 3,Not Applicable 51-61-6, 62-31-7 681
Nimodipine Approved, Investigational Phase 4 66085-59-4 4497
Donepezil Approved Phase 4,Phase 3,Phase 1 120014-06-4 3152
Cilostazol Approved, Investigational Phase 4 73963-72-1 2754
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
Buprenorphine Approved, Illicit, Investigational, Vet_approved Phase 4 52485-79-7 40400 644073
Acetaminophen Approved Phase 4,Phase 2 103-90-2 1983
Corticosterone Experimental Phase 4 50-22-6 5753
11 Parasympatholytics Phase 4
12 Serotonin Agents Phase 4,Phase 3
13 Cholinergic Antagonists Phase 4
14 Psychotropic Drugs Phase 4,Phase 3,Phase 2
15 Antidepressive Agents, Second-Generation Phase 4
16 Neurotransmitter Uptake Inhibitors Phase 4,Phase 2,Phase 3
17 Antidepressive Agents Phase 4
18 Muscarinic Antagonists Phase 4
19 Cholinergic Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
20 Serotonin Uptake Inhibitors Phase 4
21 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3,Not Applicable
22 Autonomic Agents Phase 4,Phase 2,Phase 3,Not Applicable
23 Antiparkinson Agents Phase 4,Phase 3,Not Applicable
24 Neurotransmitter Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
25 Dopamine Agents Phase 4,Phase 2,Phase 3,Not Applicable
26 Excitatory Amino Acid Antagonists Phase 4,Not Applicable
27 Excitatory Amino Acids Phase 4,Not Applicable
28 Calcium, Dietary Phase 4,Phase 2,Phase 3
29 Vasodilator Agents Phase 4,Phase 2,Phase 3
30 Antihypertensive Agents Phase 4,Phase 2,Phase 3
31 calcium channel blockers Phase 4,Phase 2,Phase 3
32 Nootropic Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
33 Cholinesterase Inhibitors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
34 Phosphodiesterase Inhibitors Phase 4,Phase 2
35 Anti-Inflammatory Agents Phase 4
36 Respiratory System Agents Phase 4
37 Platelet Aggregation Inhibitors Phase 4
38 Analgesics, Non-Narcotic Phase 4,Phase 2
39 Analgesics Phase 4,Phase 2
40 Phosphodiesterase 3 Inhibitors Phase 4
41 Anti-Inflammatory Agents, Non-Steroidal Phase 4
42 Anti-Asthmatic Agents Phase 4
43 Cyclooxygenase Inhibitors Phase 4
44 Fibrinolytic Agents Phase 4
45 Neuroprotective Agents Phase 4,Phase 3
46 Antirheumatic Agents Phase 4
47 Bronchodilator Agents Phase 4
48 Protective Agents Phase 4,Phase 3
49 Antipyretics Phase 4,Phase 2
50 Cerebrolysin Phase 4

Interventional clinical trials:

(show top 50) (show all 109)
# Name Status NCT ID Phase Drugs
1 Study of Escitalopram Versus Placebo in the Treatment of Depressive Syndrome in Alzheimer’s Disease, Vascular Dementia, and Mixed Vascular and Alzheimer’s Dementia Unknown status NCT00229333 Phase 4 Escitalopram
2 Memantine and Constraint-Induced Language Therapy in Chronic Poststroke Aphasia:A Randomized Controlled Trial Unknown status NCT00196703 Phase 4 memantine
3 Efficacy and Safety Study of Nimodipine to Prevent Mild Cognitive Impairment After Acute Ischemic Strokes Unknown status NCT01220622 Phase 4 Nimodipine;Placebo
4 Efficacy and Safety of Donepezil Hydrochloride (Aricept) in Vascular Dementia Completed NCT00165763 Phase 4 donepezil hydrochloride (Aricept)
5 Cilostazol Verse Asprin for Vascular Dementia in Poststroke Patients With White Matter Lesions Completed NCT00847860 Phase 4 Cilostazol;Aspirin
6 A Clinical Trial to Evaluate the Safety and Efficacy of 20 ml Cerebrolysin in Patients With Vascular Dementia Completed NCT00947531 Phase 4 Cerebrolysin;0.9% Saline Solution
7 Memantine and Intensive Speech-Language Therapy in Aphasia Completed NCT00640198 Phase 4 memantine;memantine;placebo
8 Efficacy of Pain Treatment on Depression in Patients With Dementia Completed NCT02267057 Phase 4 Paracetamol;Buprenorphine;Paracetamol placebo;Buprenorphine placebo
9 Imaging of Brain Amyloid Plaques in the Aging Population Enrolling by invitation NCT00950430 Phase 4 Pittsburgh Compound B (C-11 PiB);F-18 FDG;Tau (18-F-AV-1451)
10 Symptomatic Treatment of Vascular Cognitive Impairment Unknown status NCT02098824 Phase 2, Phase 3 Galantamine;Methylphenidate;Placebo
11 Efficacy and Safety of Tianzhi Granule in Mild to Moderate Vascular Dementia Completed NCT02453932 Phase 3 Tianzhi granule and placebo identified to donepezil;Donepezil and placebo identified to Tianzhi granule;Placebo
12 Rivastigmine Capsules in Patients With Probable Vascular Dementia Completed NCT00130338 Phase 3 Rivastigmine
13 Efficacy and Safety of Rivastigmine Capsules in Patients With Probable Vascular Dementia Completed NCT00099216 Phase 3 Rivastigmine
14 A Study of the Safety and Effectiveness of Galantamine Versus Placebo in the Treatment of Patients With Vascular Dementia or Mixed Dementia Completed NCT00261573 Phase 3 galantamine hydrobromide
15 A Placebo-controlled Trial to Evaluate the Safety and Efficacy of Galantamine in the Treatment of Vascular Dementia Completed NCT00035191 Phase 3 galantamine
16 Seroquel- Agitation Associated With Dementia Completed NCT00621647 Phase 3 Quetiapine Fumarate;Quetiapine Fumarate;Placebo
17 A Study of the Effectiveness and Safety of Risperidone in the Treatment of Behavioral Disturbances in Patients With Dementia Completed NCT00249158 Phase 3 Risperidone
18 Combination of Metformine/Inulin Versus Metformin on Prostate Benign Hyperplasia in Metabolic Syndrome Completed NCT02778776 Phase 3 Metformin
19 Dopamine Transporter Scintigraphy Imaging (DAT-Imaging) in Patients With Lewy Body Dementia Completed NCT00209456 Phase 3 DatSCAN
20 A Study of the Effectiveness and Safety of Risperidone in the Treatment of Behavioral Disturbances in Patients With Dementia Completed NCT00249145 Phase 3 risperidone
21 A Study of the Effectiveness and Safety of Risperidone Versus Placebo in the Treatment of Behavioral Disturbances in Patients With Dementia Completed NCT00253123 Phase 3 risperidone
22 Renew NCP-5 for the Treatment of Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild Dementia of the Alzheimer's Type Recruiting NCT03721705 Phase 3
23 Risk Reduction for Alzheimer's Disease Recruiting NCT02913664 Phase 2, Phase 3 Angiotensin II receptor blocker (ARB, losartan) and calcium channel blocker (CCB, amlodipine);Atorvastatin
24 The Healthy Patterns Study Recruiting NCT03682185 Phase 3
25 Relapse Prevention Study of Pimavanserin in Dementia-related Psychosis Recruiting NCT03325556 Phase 3 Placebo;Pimavanserin 34 mg;Pimavanserin 20 mg
26 MIND Diet Intervention and Cognitive Decline Active, not recruiting NCT02817074 Phase 3
27 Efficacy and Safety of Butylphthalide Soft Capsule for the Treatment of Vascular Dementia Not yet recruiting NCT03804229 Phase 3 Butylphthalide soft capsule;Placebo soft capsule
28 The Clinical Trial of Chinese Herbal Medicine (SaiLuoTong) Capsule Not yet recruiting NCT03789760 Phase 3 SaiLuoTong capsule;placebo
29 The Clinical Trial of Chinese Herbal Medicine SaiLuoTong Capsule Unknown status NCT01978730 Phase 2 high dose group of SaiLuoTong capsule;low dose group of SaiLuoTong;the control group
30 Effect of Zydena (Udenafil) on Cerebral Blood Flow and Peripheral Blood Viscosity Unknown status NCT01466543 Phase 2 Zydena (Udenafil);Placebo
31 Efficacy and Safety of Fufangdanshen Tablets in Mild to Moderate Vascular Dementia Completed NCT01761227 Phase 2 Fufangdanshen Tablets;Placebo
32 Study of STA-1 Capsule in Patients With Vascular Dementia (Marrow-Sea Deficiency) Completed NCT01475578 Phase 2 STA-1;Ergoloid Mesylates tablet
33 Effect of Insulin Sensitizer Metformin on AD Biomarkers Completed NCT01965756 Phase 2 Metformin;Placebos
34 DAOIB for the Treatment of Cognitive Function and Behavioral and Psychological Symptoms of Dementia Completed NCT02103673 Phase 2 DAOIB;Placebo
35 Oxidative Stress and Nutritional Supplementation Intervention Study Completed NCT01234506 Phase 2
36 Delta-THC in Dementia Completed NCT01608217 Phase 2 delta-9-tetrahydrocannabinol (delta-THC);Placebo;Acetaminophen;Acetaminophen
37 Efficacy and Safety of TMBCZG in Mild to Moderate Vascular Dementia Recruiting NCT03230071 Phase 2 TMBCZG
38 A Study to Evaluate Efficacy and Safety of BAC in Patient With Alzheimer's Disease or Vascular Dementia Recruiting NCT02886494 Phase 2 BAC;Matched placebo
39 Efficacy and Safety of MMFS in Mild AD Recruiting NCT03531684 Phase 2
40 n-3 PUFA for Vascular Cognitive Aging Active, not recruiting NCT01953705 Phase 2 Omega 3 PUFA;Placebo
41 BAC in Patient With Alzheimer's Disease or Vascular Dementia Not yet recruiting NCT02467413 Phase 2 BAC
42 Aricept to Improve Functional Tasks in Vascular Dementia Active, not recruiting NCT00457769 Phase 1 Donepezil and self-generated memory training;Donepezil and experimenter-administered memory training
43 Managing Vascular Dementia Risk Factors With SymTrend Not yet recruiting NCT03702543 Phase 1
44 Remote Ischemic Preconditioning for Subcortical Vascular Dementia Unknown status NCT03022149 Not Applicable
45 Blood-brain Barrier Leakage in Dementia. A Dynamic Contrast-enhanced MRI Study Unknown status NCT02018913
46 Korea Alzheimer's Disease Neuroimaging Initiative Unknown status NCT01979419
47 Hyperbaric Oxygen Therapy for Mild Cognitive Impairment Unknown status NCT02085330 Not Applicable
48 MRS and DTI of White Matter in Alzheimer's Disease Unknown status NCT00172900
49 Neuro-Prävention im Rahmen Des Interventionsprojektes INVADE-2 (Follow-up Studie) Unknown status NCT01126775
50 Efficiency Study of Siwu Tang to Treat Brain Hypoperfusion Syndrome Unknown status NCT01221662 Not Applicable Siwu Tang

Search NIH Clinical Center for Vascular Dementia

Cochrane evidence based reviews: dementia, vascular

Genetic Tests for Vascular Dementia

Anatomical Context for Vascular Dementia

MalaCards organs/tissues related to Vascular Dementia:

Brain, Testes, Cortex, Endothelial, Kidney, Heart, Skin

Publications for Vascular Dementia

Articles related to Vascular Dementia:

(show top 50) (show all 1352)
# Title Authors Year
Vascular dementia: clinicopathologic and genetic considerations. ( 29380913 )
Predicting outcome of Morris water maze test in vascular dementia mouse model with deep learning. ( 29415035 )
Chinese Herbal Medicine for Vascular Dementia: A Systematic Review and Meta-Analysis of High-Quality Randomized Controlled Trials. ( 29439346 )
Genomea89wide DNA methylation profiling in a rat model with vascular dementia. ( 29749552 )
Betulinic acid, a natural PDE inhibitor restores hippocampal cAMP/cGMP and BDNF, improve cerebral blood flow and recover memory deficits in permanent BCCAO induced vascular dementia in rats. ( 29778746 )
Stroke Risk and Vascular Dementia in South Asians. ( 29974259 )
Potential of carnosine, a histamine precursor in rat model of bilateral common carotid artery occlusion-induced vascular dementia. ( 29676814 )
Sleep Apnea Is a Risk Factor for Stroke and Vascular Dementia. ( 29938308 )
The involvement of neuroinflammation and necroptosis in the hippocampus during vascular dementia. ( 29759140 )
Distinct Patterns of Rich Club Organization in Alzheimer's Disease and Subcortical Vascular Dementia: A White Matter Network Study. ( 29710719 )
FoxO1-mediated autophagy plays an important role in the neuroprotective effects of hydrogen in a rat model of vascular dementia. ( 29885845 )
Neuroprotective effect of berberine chloride on cognitive impairment and hippocampal damage in experimental model of vascular dementia. ( 29372037 )
Lower Plasma Klotho Concentrations Are Associated with Vascular Dementia but Not Late-Onset Alzheimer's Disease. ( 29768278 )
Factors associated with type 2 diabetes in patients with vascular dementia: a population-based cross-sectional study. ( 29973163 )
<i>Panax ginseng</i> extract attenuates neuronal injury and cognitive deficits in rats with vascular dementia induced by chronic cerebral hypoperfusion. ( 29722318 )
Herbal medicine as a promising therapeutic approach for the management of vascular dementia: A systematic literature review. ( 29786916 )
Tau pathology and neurochemical changes associated with memory dysfunction in an optimised murine model of global cerebral ischaemia - A potential model for vascular dementia? ( 29649504 )
Molecular Pharmacology of Rosmarinic and Salvianolic Acids: Potential Seeds for Alzheimer's and Vascular Dementia Drugs. ( 29401682 )
Albuminuria Increases the Risks for Both Alzheimer Disease and Vascular Dementia in Community-Dwelling Japanese Elderly: The Hisayama Study. ( 29353232 )
Vascular Endothelial Growth Factor remains unchanged in cerebrospinal fluid of patients with Alzheimer's disease and vascular dementia. ( 29933741 )
Repeated administration of Sailuotong, a fixed combination of Panax ginseng, Ginkgo biloba, and Crocus sativus extracts for vascular dementia, alters CYP450 activities in rats. ( 29425645 )
Acupuncture Prevents the Impairment of Hippocampal LTP Through I^1-AR in Vascular Dementia Rats. ( 29435917 )
Diagnostic relevance of spatial orientation for vascular dementia: A case study. ( 29682239 )
Neuropsychiatric symptoms in vascular dementia: Epidemiologic and clinical aspects. ( 29682232 )
Ligustrazine suppresses neuron apoptosis via the Bax/Bcl-2 and caspase-3 pathway in PC12 cells and in rats with vascular dementia. ( 29247598 )
Specific Patterns of White Matter Alterations Help Distinguishing Alzheimer's and Vascular Dementia. ( 29922120 )
Intermittent streptozotocin administration induces behavioral and pathological features relevant to Alzheimer's disease and vascular dementia. ( 29738850 )
Efficacy and safety of the compound Chinese medicine SaiLuoTong inA vascular dementia: A randomized clinical trial. ( 29955654 )
Puerarin up-regulates methyl-CpG binding protein 2 phosphorylation in hippocampus of vascular dementia rats. ( 29327124 )
Nanotherapy for Alzheimer's disease and vascular dementia: Targeting senile endothelium. ( 29274774 )
Mitochondrial factor and cell cytokines associate with TCM syndrome scale in vascular dementia patients. ( 29375680 )
The potential protective effects of cannabinoid receptor agonist WIN55,212-2 on cognitive dysfunction is associated with the suppression of autophagy and inflammation in an experimental model of vascular dementia. ( 29945070 )
Aging and cerebrovascular lesions in pure and in mixed neurodegenerative and vascular dementia brains: a neuropathological study. ( 30509027 )
Inhibitory Control, Task/Rule Switching, and Cognitive Planning in Vascular Dementia: Are There Any Differences From Vascular Aging? ( 30410439 )
An Estimate of Attributable Cases of Alzheimer Disease and Vascular Dementia due to Modifiable Risk Factors: The Impact of Primary Prevention in Europe and in Italy. ( 29606955 )
Anxiety as a risk factor of Alzheimer's disease and vascular dementia - ERRATUM. ( 30334505 )
Anxiety as a risk factor of Alzheimer's disease and vascular dementia. ( 30339108 )
Dysfunction of Cerebrovascular Endothelial Cells: Prelude to Vascular Dementia. ( 30505270 )
Atherosclerosis, Hypertension, and Diabetes in Alzheimer's Disease, Vascular dementia, and Mixed Dementia: Prevalence and Presentation. ( 30507582 )
Traditional Chinese herbal medicine for vascular dementia. ( 30520514 )
Resveratrol prevents cognitive deficits by attenuating oxidative damage and inflammation in rat model of streptozotocin diabetes induced vascular dementia. ( 30550811 )
Fastigial nucleus stimulation ameliorates cognitive impairment via modulating autophagy and inflammasomes activation in a rat model of vascular dementia. ( 30552710 )
Berberine suppresses the ectopic expression of miR-133a in endothelial cells to improve vascular dementia in diabetic rats. ( 30472896 )
Targeted Assessment of Enlargement of the Perivascular Space in Alzheimer's Disease and Vascular Dementia Subtypes Implicates Astroglial Involvement Specific to Alzheimer's Disease. ( 30475760 )
MicroRNA-210-5p Contributes to Cognitive Impairment in Early Vascular Dementia Rat Model Through Targeting Snap25. ( 30483048 )
Association of hyperglycemia episodes on long-term mortality in type 2 diabetes mellitus with vascular dementia: A population-based cohort study. ( 30420126 )
Effects of acupuncture on vascular dementia (VD) animal models: a systematic review and meta-analysis. ( 30424749 )
CZ-7, a new derivative of Claulansine F, ameliorates 2VO-induced vascular dementia in rats through a Nrf2-mediated antioxidant responses. ( 30382185 )
Effect of medicated thread moxibustion on apoptosis of hippocampal neurons in rat models of chronic cerebral ischemic vascular dementia. ( 30403605 )
Vascular dementia encoding in the French nationwide discharge summary database (PMSI): Variability over the 2007-2017 period. ( 30409382 )

Variations for Vascular Dementia

ClinVar genetic disease variations for Vascular Dementia:

# Gene Variation Type Significance SNP ID Assembly Location
1 TNF NM_000594.3(TNF): c.-1037C> T single nucleotide variant risk factor rs1799724 GRCh37 Chromosome 6, 31542482: 31542482
2 TNF NM_000594.3(TNF): c.-1037C> T single nucleotide variant risk factor rs1799724 GRCh38 Chromosome 6, 31574705: 31574705

Expression for Vascular Dementia

Search GEO for disease gene expression data for Vascular Dementia.

Pathways for Vascular Dementia

GO Terms for Vascular Dementia

Cellular components related to Vascular Dementia according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 endoplasmic reticulum lumen GO:0005788 9.8 APOE APP BCHE CST3
2 membrane raft GO:0045121 9.73 APP MAPT PSEN1 TNF
3 extracellular space GO:0005615 9.65 ACE ACHE APOE APP BCHE CST3
4 neuromuscular junction GO:0031594 9.63 ACHE APP PSEN1
5 cell surface GO:0009986 9.63 ACHE APP MBP PSEN1 TNF VEGFA
6 blood microparticle GO:0072562 9.56 APOE BCHE PON1 SERPINA3
7 platelet alpha granule lumen GO:0031093 9.54 APP SERPINA3 VEGFA
8 synaptic cleft GO:0043083 9.51 ACHE APOE
9 ciliary rootlet GO:0035253 9.48 APP PSEN1
10 nuclear envelope lumen GO:0005641 9.4 APP BCHE
11 extracellular region GO:0005576 9.4 ACE ACHE APOE APP BCHE CST3
12 main axon GO:0044304 9.32 APP MAPT

Biological processes related to Vascular Dementia according to GeneCards Suite gene sharing:

(show all 33)
# Name GO ID Score Top Affiliating Genes
1 cellular protein metabolic process GO:0044267 9.85 APOE APP CST3 PSEN1
2 response to oxidative stress GO:0006979 9.83 APOE APP PSEN1
3 platelet degranulation GO:0002576 9.83 APP SERPINA3 VEGFA
4 negative regulation of peptidase activity GO:0010466 9.82 APP CST3 SERPINA3
5 Notch signaling pathway GO:0007219 9.82 APP NOTCH3 PSEN1
6 positive regulation of protein phosphorylation GO:0001934 9.81 APP PSEN1 TNF VEGFA
7 cholesterol metabolic process GO:0008203 9.79 APOE APP PON1
8 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.78 APP TNF VEGFA
9 forebrain development GO:0030900 9.75 APP NOTCH3 PSEN1
10 positive regulation of protein binding GO:0032092 9.73 ACE APP PSEN1
11 positive regulation of MAP kinase activity GO:0043406 9.7 PSEN1 TNF VEGFA
12 microglial cell activation GO:0001774 9.65 MAPT TNF
13 synapse organization GO:0050808 9.65 APP MAPT PSEN1
14 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.64 APOE TNF
15 positive regulation of cholesterol efflux GO:0010875 9.63 APOE PON1
16 amyloid-beta metabolic process GO:0050435 9.63 ACE PSEN1
17 negative regulation of gene expression GO:0010629 9.63 ACE APOE APP MAPT TNF VEGFA
18 neurotransmitter biosynthetic process GO:0042136 9.62 ACHE CHAT
19 supramolecular fiber organization GO:0097435 9.62 CST3 MAPT
20 negative regulation of long-term synaptic potentiation GO:1900272 9.6 APOE APP
21 neuron projection maintenance GO:1990535 9.59 APP PSEN1
22 amyloid fibril formation GO:1990000 9.58 APP MAPT
23 response to folic acid GO:0051593 9.57 BCHE MTHFR
24 modulation of age-related behavioral decline GO:0090647 9.54 APP PSEN1
25 artery morphogenesis GO:0048844 9.5 APOE NOTCH3 VEGFA
26 negative regulation of low-density lipoprotein receptor activity GO:1905598 9.49 APP PSEN1
27 positive regulation of peptidyl-tyrosine autophosphorylation GO:1900086 9.46 ACE VEGFA
28 regulation of epidermal growth factor-activated receptor activity GO:0007176 9.43 APP PSEN1
29 amyloid precursor protein metabolic process GO:0042982 9.43 ACHE APOE PSEN1
30 astrocyte activation involved in immune response GO:0002265 9.4 APP PSEN1
31 smooth endoplasmic reticulum calcium ion homeostasis GO:0051563 9.37 APP PSEN1
32 positive regulation of amyloid fibril formation GO:1905908 9.13 APOE APP PSEN1
33 astrocyte activation GO:0048143 8.92 APP MAPT PSEN1 TNF

Molecular functions related to Vascular Dementia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 peptidase inhibitor activity GO:0030414 9.58 APP CST3 SERPINA3
2 identical protein binding GO:0042802 9.56 APOE APP BCHE CST3 MAPT NOTCH3
3 protease binding GO:0002020 9.54 CST3 MBP TNF
4 lipoprotein particle binding GO:0071813 9.32 APOE MAPT
5 cholinesterase activity GO:0004104 9.26 ACHE BCHE
6 acetylcholinesterase activity GO:0003990 9.16 ACHE BCHE
7 amyloid-beta binding GO:0001540 8.92 ACHE APOE BCHE CST3

Sources for Vascular Dementia

9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
32 HPO
33 ICD10
34 ICD10 via Orphanet
38 LifeMap
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
55 Novoseek
58 OMIM via Orphanet
62 PubMed
70 SNOMED-CT via Orphanet
72 Tocris
74 UMLS via Orphanet
Loading form....